Sun Hit As US FDA Raises Fresh Concerns Over Key Halol Plant

08 Dec 2016

• By Penelope MacRae

Indian generic giant Sun Pharma says the US FDA has flagged up new potential violations of good manufacturing practices at the company's key Halol factory, which exports a large number of products to the crucial US market and had been expected to overcome its past compliance problems.

Sun Pharmaceutical Industries Ltd.'s shares had been rising on investor optimism that US Food and Drug Administration inspectors would give the all-clear to the company’s flagship Halol plant after their visit last month to the factory, located in India's western Gujarat state.

But instead the FDA team found new potential breaches of good manufacturing practices at Halol, Sun Pharma disclosed Dec. 7...